PH12022551650A1 - Anti-trem2 antibodies and methods of use thereof - Google Patents
Anti-trem2 antibodies and methods of use thereofInfo
- Publication number
- PH12022551650A1 PH12022551650A1 PH1/2022/551650A PH12022551650A PH12022551650A1 PH 12022551650 A1 PH12022551650 A1 PH 12022551650A1 PH 12022551650 A PH12022551650 A PH 12022551650A PH 12022551650 A1 PH12022551650 A1 PH 12022551650A1
- Authority
- PH
- Philippines
- Prior art keywords
- trem2
- methods
- trem2 antibodies
- antibodies
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960663P | 2020-01-13 | 2020-01-13 | |
| US202063070728P | 2020-08-26 | 2020-08-26 | |
| US202063091717P | 2020-10-14 | 2020-10-14 | |
| PCT/US2021/013200 WO2021146256A1 (en) | 2020-01-13 | 2021-01-13 | Anti-trem2 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022551650A1 true PH12022551650A1 (en) | 2024-02-12 |
Family
ID=74587108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/551650A PH12022551650A1 (en) | 2020-01-13 | 2021-01-13 | Anti-trem2 antibodies and methods of use thereof |
Country Status (17)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗trem2抗体及びその使用方法 |
| BR112022012230A2 (pt) | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| MX2024010324A (es) | 2022-02-23 | 2024-08-30 | Alector Llc | Metodos de uso de anticuerpos anti-trem2. |
| EP4499693A1 (en) | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| EP4499695A1 (en) | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| WO2024253424A1 (ko) * | 2023-06-09 | 2024-12-12 | 재단법인대구경북과학기술원 | 인간 trem2 단백질에 특이적으로 결합하는 인간화 항체 및 이의 용도 |
| WO2024253420A1 (ko) * | 2023-06-09 | 2024-12-12 | 재단법인대구경북과학기술원 | 인간 trem2 단백질에 특이적으로 결합하는 인간 항체 및 이의 용도 |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
| WO2026062582A1 (en) * | 2024-09-20 | 2026-03-26 | Novartis Ag | Methods of treatment using anti-trem2 antibodies |
| WO2026062585A1 (en) * | 2024-09-20 | 2026-03-26 | Novartis Ag | Methods of treatment using anti-trem2 antibodies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10087408B2 (en) | 2010-07-07 | 2018-10-02 | The University Of British Columbia | System and method for microfluidic cell culture |
| US9188593B2 (en) | 2010-07-16 | 2015-11-17 | The University Of British Columbia | Methods for assaying cellular binding interactions |
| EA201790342A1 (ru) * | 2014-08-08 | 2017-07-31 | ЭЛЕКТОР ЭлЭлСи | Антитела к trem2 и способы их применения |
| JP7725185B2 (ja) * | 2015-10-06 | 2025-08-19 | アレクトル エルエルシー | 抗trem2抗体及びその使用方法 |
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| EP4628586A3 (en) | 2017-02-17 | 2026-01-14 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| HUE062436T2 (hu) | 2017-08-03 | 2023-11-28 | Alector Llc | Anti-trem2 antitestek és alkalmazási módszereik |
| WO2019055841A1 (en) * | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| CN113302206A (zh) | 2018-11-26 | 2021-08-24 | 戴纳立制药公司 | 治疗脂质代谢失调的方法 |
| JP7543290B2 (ja) * | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗trem2抗体及びその使用方法 |
-
2021
- 2021-01-13 WO PCT/US2021/013200 patent/WO2021146256A1/en not_active Ceased
- 2021-01-13 JP JP2022542652A patent/JP7870250B2/ja active Active
- 2021-01-13 KR KR1020227025637A patent/KR20220131246A/ko active Pending
- 2021-01-13 CN CN202180008986.5A patent/CN115279790A/zh active Pending
- 2021-01-13 PE PE2022001437A patent/PE20221465A1/es unknown
- 2021-01-13 IL IL294655A patent/IL294655A/en unknown
- 2021-01-13 EP EP21704639.0A patent/EP4090682A1/en active Pending
- 2021-01-13 AU AU2021208482A patent/AU2021208482B2/en active Active
- 2021-01-13 MX MX2022008582A patent/MX2022008582A/es unknown
- 2021-01-13 PH PH1/2022/551650A patent/PH12022551650A1/en unknown
- 2021-01-13 TW TW110101213A patent/TWI890727B/zh active
- 2021-01-13 CA CA3166385A patent/CA3166385A1/en active Pending
- 2021-01-13 BR BR112022013756A patent/BR112022013756A2/pt unknown
- 2021-09-17 US US17/478,587 patent/US20220177576A1/en not_active Abandoned
-
2022
- 2022-07-12 CL CL2022001886A patent/CL2022001886A1/es unknown
- 2022-07-12 EC ECSENADI202254464A patent/ECSP22054464A/es unknown
- 2022-07-12 CO CONC2022/0009744A patent/CO2022009744A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4090682A1 (en) | 2022-11-23 |
| KR20220131246A (ko) | 2022-09-27 |
| MX2022008582A (es) | 2022-08-10 |
| US20220177576A1 (en) | 2022-06-09 |
| CN115279790A (zh) | 2022-11-01 |
| JP7870250B2 (ja) | 2026-06-04 |
| BR112022013756A2 (pt) | 2022-10-11 |
| WO2021146256A1 (en) | 2021-07-22 |
| TWI890727B (zh) | 2025-07-21 |
| CO2022009744A2 (es) | 2022-07-19 |
| CL2022001886A1 (es) | 2023-03-24 |
| JP2023512450A (ja) | 2023-03-27 |
| ECSP22054464A (es) | 2022-08-31 |
| AU2021208482A1 (en) | 2022-07-21 |
| PE20221465A1 (es) | 2022-09-21 |
| AU2021208482B2 (en) | 2025-12-11 |
| TW202128771A (zh) | 2021-08-01 |
| CA3166385A1 (en) | 2021-07-22 |
| IL294655A (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022008582A (es) | Anticuerpos anti-trem2 y metodos para utilizarlos. | |
| PH12021552002A1 (en) | Anti-trem2 antibodies and methods of use thereof | |
| PT2287195T (pt) | Anticorpos de recetor de nk de pan-kir2dl e a sua utilização em diagnóstico e terapêutica | |
| SG163615A1 (en) | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity | |
| EP1470146B8 (en) | Antibodies against the muc18 antigen | |
| EP1485130A4 (en) | REAGENTS AND THERAPEUTIC METHODS OF AUTOIMMUNE DISEASES | |
| TW200714711A (en) | Anti-cd-20 monoclonal antibody | |
| EP1467757A4 (en) | USE OF ANTIBODIES TO THE MUC18 ANTIGEN | |
| MY199319A (en) | Anti-pd-l1 antibody and use thereof | |
| WO2006116592A3 (en) | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells | |
| NZ605429A (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
| MX2023008000A (es) | Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos. | |
| TW221675B (cg-RX-API-DMAC7.html) | ||
| WO2020086406A3 (en) | Anti-npr1 antibodies and uses thereof | |
| MX2024007390A (es) | Anticuerpo completamente humanizado y receptor de antigeno quimerico (car) dirigido al subtipo d de la familia c5 del receptor acoplado a proteina g (gprc5d) y usos del mismo. | |
| JOP20230106A1 (ar) | جسم مضاد ثنائي النوعية لـ tspan8/cd3 وجسم مضاد لـ tspan8 | |
| TW272197B (cg-RX-API-DMAC7.html) | ||
| UA94211C2 (ru) | Выделенное полностью человеческое моноклональное cd3 антитело | |
| MX2024006812A (es) | Anticuerpos antagonistas anti-npr1 y metodos de uso de los mismos. | |
| MX2021008453A (es) | Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos. |